The research shows that as long as essential genes remain intact, our genomes can tolerate significant structural changes, ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

The CRISPR-Cas9 platform will be used to delete the PD-1 gene in T cells extracted from trial participant’s blood. In healthy cells, an activated PD-1 gene results in the production of the PD-1 ...

The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or embryos tinkers with DNA far beyond ... the disgraced scientist first to experiment with editing human embryos, to jail ...

"As CRISPR therapies enter the clinic ... by these predictions and tested the most promising candidates in human cells and in mice that were genetically modified to bear key components of the ...

And in December, it shelved a sickle cell treatment similar to Casgevy, the treatment approved in late 2023 from Vertex and CRISPR Therapeutics. Casgevy’s slow rollout — it appears to have ...

In December 2023, the FDA approved the first Crispr-based therapy for sickle cell disease ... of mice that have been engineered to carry the human progeria mutation. Our team is now working ...

Sickle cell disease research news: STAT looks at new CRISPR-based treatment possibilities, and asks when sickle cell gene therapies will become widely available. For more on Oxbryta, Adakveo ...

Editas and CRISPR are probably most closely linked as they both pursued Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) early on. Despite this similarity, the two ...

CRISPR, is a technology that can edit DNA at precise locations in the human genome ... technique to alter the expression of genes in cells in the lab, which can then be administered to patients ...